The State of U.S. Medical Aesthetics: A Cross-Sectional Analysis of 50,000 Practices, January–August 2026

1. Introduction

Market breakdowns of the U.S. aesthetics industry circulate widely on professional networks, and their headline figures are frequently repeated without verification. Because downstream statistics inherit upstream errors, misstatements about market composition propagate quickly. This report takes a different approach: rather than estimating the market, it observes it, at the level of the individual practice, across 50,000 U.S. aesthetic businesses.

2. Methods

2.1 Data sources

Practice-level data were compiled from publicly available sources (practice websites, business listings, review platforms, and public social media activity) and structured, categorized, and scored by Fathom's AI engine into a proprietary intelligence layer. Of the 50,000 practices in the analysis, 26,323 carry fully enriched profiles including detected services, device inventories, staffing signals, and reputation metrics. In addition, 503,000+ posts authored by these practices on public social channels were analyzed for treatment and device mentions.

2.2 Demand measurement

Patient demand was measured as U.S. Google monthly search volume per treatment term. Because aesthetics search behavior is strongly seasonal (peaking each January), single-month comparisons overstate decline. Trends are therefore computed as the mean monthly volume for January–May 2026 versus the mean for July–December 2025. June 2026 was excluded due to reporting lag.

2.3 Interpretation of counts

Offering counts reflect what practices publicly market, which may differ from clinical volume delivered. Share-of-market figures are reported against categorized practices only; approximately 7,850 profiles could not be confidently categorized and are excluded from composition percentages.

3. Results

3.1 Practice composition

Table 1. Distribution of practice types among fully profiled practices (n = 26,323), with mean Google rating and review count.

Ratings for plastic surgery and general categories are suppressed pending data-quality review of null-heavy segments. Med spa row merges two source labels.

3.2 Treatment and device prevalence

Table 2. Most frequently offered treatments and devices among profiled practices (n = 26,323), by website mention.

Within the neurotoxin category, for every 100 practices offering Botox, approximately 51 offer Dysport, 24 Xeomin, 14 Jeuveau, and 14 Daxxify. Challenger toxins have achieved meaningful distribution; Section 3.3 indicates they have not achieved comparable patient demand.

3.3 Patient search demand

Table 3. Mean U.S. Google monthly search volume, January–June 2026, and change versus the July–December 2025 baseline.

3.4 Geographic distribution

Table 4. Leading states by practice count within the analysis.

California, Florida, and Texas jointly account for approximately as many practices as the next seven states combined. Relative to population rank, Arizona and Maryland are over-represented, consistent with concentration in sunbelt-retiree and capital-suburb corridors.

4. Discussion

Four claims that circulate widely in industry commentary are inconsistent with the observed data.

1. "Aesthetics means med spas." Med spas constitute 25.7% of categorized practices. The majority of the market is full-service, surgical, dermatologic, or specialty, and these segments differ in reputation profile and purchasing behavior.
2. "Botulinum toxin demand is accelerating." Botox search demand declined 7% in 2026. Growth concentrated instead in adjacent categories: GLP-1 agents (+21% on an eightfold larger base), resurfacing and energy-based treatments (+29% to +38%), and biostimulatory injectables (+25%).
3. "Review scores no longer differentiate practices." Star ratings cluster near the ceiling, but review counts do not: the dermatology mean (478) is more than triple the med-spa mean (~150). Volume, not rating, is the discriminating reputation variable.
4. "Body contouring collapsed after the cryolipolysis backlash." CoolSculpting demand is flat rather than declining, roughly 1,500 practices continue to market it, and Emsculpt demand grew 13% in 2026. The category rotated across modalities; aggregate demand persisted.

A consistent pattern across Tables 2 and 3 is a supply–demand mismatch in high-growth categories. Sculptra, with demand up 25%, is offered by fewer than half as many practices as Botox; comparable gaps appear in skin tightening (Ultherapy, Sofwave) and RF microneedling. Conversely, regenerative topics (exosomes, polynucleotides) show 2025 demand spikes that retreated in 2026 even as 850+ practices began marketing them, a supply overshoot characteristic of a cooling hype cycle.

5. Limitations

• This is an observational, cross-sectional analysis; offering counts measure public marketing, not procedures performed.
• Practice categorization is algorithmic; approximately 7,850 practices could not be confidently categorized and are excluded from composition percentages. The analysis population is rounded from 49,289 tracked practices.
• Search volumes are reported in the ad platform's bucketed values; small differences between terms are not meaningful.
• Mean ratings for two categories are withheld pending data-quality review; social-post volume over time is not reported because collection coverage expanded during the study window.

6. Conclusion

Measured directly, the U.S. aesthetics market is larger, more heterogeneous, and differently weighted than prevailing commentary suggests. Demand is rotating toward skin rebuilding, biostimulation, and weight-management-adjacent services while several of those categories remain under-supplied at the practice level. For manufacturers and commercial leaders, the actionable signal is the measurable gap between what patients search for and what nearby practices offer.